Last updated: May 2026
This guide covers the dose escalation schedule for compounded tirzepatide, how to calculate draw volume from a vial, injection preparation, and common questions. It is a mathematical and procedural reference — not medical advice. Always follow your prescriber's specific instructions.
Need to convert your tirzepatide dose to mL? Use the calculator for exact draw volumes and U-100 units from any vial concentration.
Open Calculator →Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It activates both receptor pathways, promoting insulin secretion in response to meals, reducing appetite, and slowing gastric emptying. Compounded tirzepatide is produced by compounding pharmacies and supplied in multi-dose vials rather than pre-filled autoinjector pens.
Because doses range from 2.5 mg to 15 mg weekly — significantly higher in absolute mg than semaglutide — compounded tirzepatide is commonly available at higher concentrations (5 or 10 mg/mL) to keep draw volumes within a practical range for insulin syringes.
Tirzepatide is introduced at a low starting dose and increased gradually. The schedule below reflects common escalation steps — your prescriber may modify the timing or increment size based on your individual response:
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg/week | Starting dose — tolerance development |
| 5–8 | 5 mg/week | First increase if tolerated |
| 9–12 | 7.5 mg/week | Continue if tolerating well |
| 13–16 | 10 mg/week | Continue escalation |
| 17–20 | 12.5 mg/week | Near-maximum dose |
| 21+ | 15 mg/week | Maximum maintenance dose |
Common side effects during dose escalation include nausea, diarrhoea, decreased appetite, and fatigue. These are usually most pronounced in the first 2–4 weeks after each increase and often improve over time. Some protocols extend each dose level to 8 weeks rather than 4 if side effects are significant.
Divide your prescribed dose in mg by the vial concentration in mg/mL:
Draw (mL) = Dose (mg) ÷ Concentration (mg/mL)
Concentration: 10 mg/mL
Dose: 7.5 mg
Draw = 7.5 ÷ 10 = 0.75 mL = 75 units (U-100 syringe)
On a U-100 insulin syringe, 1 unit = 0.01 mL. To convert mL to units, multiply by 100. The InjectBuddy calculator handles this automatically.
Calculate exact draw volume and syringe units for any tirzepatide dose and vial concentration.
Tirzepatide Calculator →| Dose | 2.5 mg/mL vial | 5 mg/mL vial | 10 mg/mL vial |
|---|---|---|---|
| 2.5 mg | 1.00 mL (100 U) | 0.50 mL (50 U) | 0.25 mL (25 U) |
| 5 mg | 2.00 mL (200 U) | 1.00 mL (100 U) | 0.50 mL (50 U) |
| 7.5 mg | 3.00 mL (300 U) | 1.50 mL (150 U) | 0.75 mL (75 U) |
| 10 mg | 4.00 mL (400 U) | 2.00 mL (200 U) | 1.00 mL (100 U) |
| 12.5 mg | 5.00 mL (500 U) | 2.50 mL (250 U) | 1.25 mL (125 U) |
| 15 mg | 6.00 mL (600 U) | 3.00 mL (300 U) | 1.50 mL (150 U) |
At doses of 10–15 mg, a 2.5 mg/mL vial is impractical (4–6 mL draw). A 10 mg/mL vial keeps all doses within 0.25–1.50 mL, which fits a standard 1.5 mL or 2 mL syringe.
Store compounded tirzepatide vials refrigerated at 2–8°C (36–46°F). Do not freeze. Check with your pharmacy for specific room-temperature stability data for your product. Protect from light and check the expiry date on the label before each injection.
The dose escalation schedule in this guide reflects the protocol studied in the SURMOUNT-1 trial (tirzepatide 5, 10, and 15 mg/week for weight management in adults with obesity). The SURMOUNT-2 trial confirmed efficacy in adults with obesity and type 2 diabetes. Compounded tirzepatide is not covered by these trials — they used Eli Lilly's branded formulation. Always follow your prescriber's specific escalation schedule.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. · Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Lancet. 2023;402:613–626.